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Abstract
Background: Aggregates formed between leukocytes and platelets in the circulation lead to release of tissue factor (TF)–
bearing microparticles contributing to a prothrombotic state. As enterohemorrhagic Escherichia coli (EHEC) may cause
hemolytic uremic syndrome (HUS), in which microthrombi cause tissue damage, this study investigated whether the
interaction between blood cells and EHEC virulence factors Shiga toxin (Stx) and lipopolysaccharide (LPS) led to release of
TF.
Methodology/Principal Findings: The interaction between Stx or LPS and blood cells induced platelet-leukocyte aggregate
formation and tissue factor (TF) release, as detected by flow cytometry in whole blood. O157LPS was more potent than
other LPS serotypes. Aggregates formed mainly between monocytes and platelets and less so between neutrophils and
platelets. Stimulated blood cells in complex expressed activation markers, and microparticles were released. Microparticles
originated mainly from platelets and monocytes and expressed TF. TF–expressing microparticles, and functional TF in
plasma, increased when blood cells were simultaneously exposed to the EHEC virulence factors and high shear stress. Stx
and LPS in combination had a more pronounced effect on platelet-monocyte aggregate formation, and TF expression on
these aggregates, than each virulence factor alone. Whole blood and plasma from HUS patients (n=4) were analyzed. All
patients had an increase in leukocyte-platelet aggregates, mainly between monocytes and platelets, on which TF was
expressed during the acute phase of disease. Patients also exhibited an increase in microparticles, mainly originating from
platelets and monocytes, bearing surface-bound TF, and functional TF was detected in their plasma. Blood cell aggregates,
microparticles, and TF decreased upon recovery.
Conclusions/Significance: By triggering TF release in the circulation, Stx and LPS can induce a prothrombotic state
contributing to the pathogenesis of HUS.
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Introduction
Platelets and leukocytes do not interact with each other in the
circulation under normal circumstances. Enhanced platelet-
leukocyte interactions occur in vivo in vascular disease processes,
such as unstable angina, acute myocardial infarction, and stroke
[1], in polycythemia vera [2] and diabetes [3] as well as during
vascular surgical procedures such as cardiopulmonary bypass [1]
and aortic valve surgery [4]. The formation of platelet-leukocyte
aggregates plays an important role in the initiation of thrombo-
genesis and inflammation [5]. Upon platelet activation, P-selectin
is released and expressed on the cell surface. Binding of P-selectin
to its ligand P-selectin glycoprotein ligand 1 (PSGL-1), constitu-
tively expressed on all leukocytes, mediates the formation of
platelet-leukocyte aggregates in the circulation and on damaged
vascular surfaces on which platelets and fibrin have been deposited
[1]. Leukocytes can roll on activated platelets enabling binding
and migration into inflammatory tissues. Binding of platelets to
monocytes and neutrophils results in expression of the integrin
CD11b/CD18 which enables further aggregate formation by
interaction with the GPIb receptor on platelets [6], alternatively
with fibrinogen bound to the GPIIb/IIIa receptor [7] expressed on
activated platelets. Activated platelets, monocytes and neutrophils
release microparticles which express tissue factor (TF) [8,9,10].
TF is a transmembrane cell surface glycoprotein that acts as a
receptor for coagulation factor VII/VIIa, catalyzes the conversion
of factor X to the active form Xa and ultimately leads to thrombin
formation. Thrombin converts fibrinogen to fibrin resulting in
formation of an insoluble fibrin clot [11]. In addition, thrombin is
a potent stimulator of platelet activation [12]. Excessive expression
of TF occurs in prothrombotic conditions such as sepsis,
endotoxemia, systemic lupus erythematosus, atherosclerosis,
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uremic syndrome (HUS) [13,14,15,16,17,18].
HUS develops as a complication of Shiga toxin (Stx)-producing
enterohemorrhagic Escherichia coli (EHEC) infection of which
serotype O157:H7 is the most commonly detected. HUS is
characterized by non-immune hemolytic anemia, thrombocyto-
penia and acute renal failure [19]. HUS is a prothrombotic state in
which platelets are activated and fibrinolysis is decreased
[20,21,22]. The mechanisms by which thrombotic microangiop-
athy occurs during HUS have not been fully elucidated. Stx may
contribute to the process by inducing endothelial cell damage [23]
an effect enhanced in the presence of lipopolysaccharide (LPS)
[24] which increases Stx binding [25]. Stx promotes platelet
deposition on endothelial cells exposed to high shear stress [26].
Endothelial cell injury could, potentially, expose the subendothe-
lium releasing thrombogenic factors, such as fibrinogen and von
Willebrand factor, which could trigger platelet aggregation.
Furthermore, Stx can interact directly with platelets inducing
their activation [27].
In the present study the effects of Stx2 and LPS on platelet-
leukocyte aggregate formation and TF expression were investigat-
ed in order to identify a prothrombotic mechanism contributing to
thrombotic microangiopathy. The in vivo relevance of platelet-
leukocyte aggregate formation and TF expression was studied in
samples from HUS patients.
Materials and Methods
Subjects
Venous blood was obtained from 25 human healthy volunteers
(16 women, 9 men) not using any medications. Blood samples were
also available from three boys and one girl aged 1–9 years (median
2 years), diagnosed with EHEC-associated HUS and treated at the
Department of Pediatrics, Lund University Hospital. Patient
samples were taken on the first day after admission, while the
children had clinical signs of HUS. HUS was defined as hemolytic
anemia (hemoglobin levels ,100 g/L), elevated lactic dehydroge-
nase, thrombocytopenia (platelet counts ,140610
9/L) and acute
renal failure. Blood was also obtained from all four children two to
four months after recovery. Laboratory diagnosis of EHEC
infection was determined by PCR and serotyping of fecal isolate
serotypes [28]. Fecal isolates were positive for Stx2-producing E.
coli O157:H7 in three cases and in the fourth case for Stx1- and
Stx2- producing E. coli O98:H21. Samples were also available
from 4 pediatric controls, 3 boys and 1 girl, aged 5–11 years
(median 6.5 years). These children were seen at the out-patient
clinic of the Department of Pediatrics, Lund University Hospital,
for follow-up of posterior urethral valve, recurrent urinary tract
infections or neuroblastoma. None of the pediatric controls had a
history of diarrhea or HUS. Samples were also obtained from
three patients with acute renal failure, 2 males aged 25 and 62
years, respectively, and one girl from which blood was obtained at
7 days of age. The adult patients were treated at the Department
of Nephrology of the University Hospitals of Malmo ¨ and Lund for
renal failure due to vitamin D intoxication and acute tubular
necrosis, respectively. The child was treated at the Department of
Pediatrics, Lund University Hospital for renal failure after heart
surgery.
Ethics statement
Samples from healthy donors, patients and pediatric controls
were taken with the informed written consent of the subjects or
their parents and with the approval of the Ethics Committee of the
Medical Faculty, Lund University.
Blood collection
Blood was drawn by venipuncture via a butterfly needle (Plasti
Medical S.p.A, Villamarzana, Italy) with low tourniquet or through an
intravenous cannula (Neoflon
TMCannula, Becton Dickinson, Franklin
L a k e s ,N J ) .T h ef i r s t2m Lw e r ed i s c a r d e da n dt h er e q u i r e dv o l u m e
collected into plastic tubes containing 0.27 mL 0.109 M sodium citrate
(Becton Dickinson, Plymouth, UK) or heparin (68 IU, Beckton
Dickinson). After blood sampling the blood was diluted (1:2) in sterile
LPS-free RPMI-1640 (Invitrogen, Paisley,UK) containing Gly-Pro-
A r g - P r o( G P R P ,1 0m M ;S i g m a - A l d r i c h ,S t .L o u i s ,M O ) ,t op r e v e n t
the polymerization of fibrin molecules. Samples were used as whole
blood (sodium citrate) in flow cytometry and flow chamber perfusion
experiments or centrifuged at 20006g for 15 minutes to obtain platelet-
poor-plasma used to quantify microparticles or for tissue factor activity
assays. Plasma was stored at 280uC until used. Heparinized samples
were used for purification of leukocytes as described below.
Study design
Stimulation of whole blood by Stx2 or LPS. Whole blood
diluted in RPMI-1640/GPRP was incubated with purified Stx2
(200 pg/mL, final concentration in all experiments, diluted in
phosphate-buffered saline (PBS, pH 7.4, Medicago, Uppsala;
Sweden)) a gift from T.G. Obrig, Department of Microbiology
and Immunology, University of Maryland School of Medicine,
Baltimore), LPS (purified by phenol extraction and used at 0.5 mg/
mL or 1 mg/mL, final concentration in all experiments defined by
the limulus amebocyte lysate assay, LAL, Coatex, Gothenburg,
Sweden) from E. coli O103:H2, O111:HN, O121:H19 (a gift from
P.I. Tarr, Division of Pediatrics, Washington University School of
Medicine, St Louis, MO) [29], O157:H7 (a gift from R. Johnson,
Public Health Agency of Canada, Guelph, Canada), non-EHEC-
LPS O111:B4 (Sigma Aldrich) or a combination of Stx2/LPS or
PBS for 4 h at 37uC. The LPS content of the Stx2 preparation was
assayed by the LAL assay and found to be less than 50 pg/mL
LPS (the detection limit).
Detection of platelet-leukocyte aggregates
To detect platelet-monocyte aggregates whole blood was
incubated with mouse anti-human CD42b:RPE-Cy5 (1:50, to
detect GP1b on platelets) and mouse anti-human CD38:FITC
(1:40, to detect monocytes), simultaneously or mouse IgG1:RPE-
Cy5 (1:50) and mouse IgG1:FITC (1:40) as the isotype controls for
10 minutes at room temperature (all antibodies from BD
Biosciences, San Diego, CA). Similarly, platelet-neutrophil aggre-
gates were detected by simultaneous incubation with mouse anti-
human CD42b:RPE-Cy5 and mouse IgManti-human CD66:FITC
(1:40, BD Biosciences, to detect neutrophils), or mouse IgG1:RPE-
Cy5 and mouse IgM:FITC (1:40, BD Biosciences) as the antibody
controls for 10 minutes at room temperature. Erythrocytes were
lysed by incubation with FACSLyse (Dako, Glostrup, Denmark).
Samples were stored at 4uC and analyzed by flow cytometry within
30 minutes of lysis. Events staining positively for both platelet and
monocyte antigens or platelet and neutrophil antigens were
considered to represent blood cell aggregates, as assayed by flow
cytometry described below.
Detection of platelet and leukocyte activation
To demonstrate the activation-dependent integrin receptor
GPIIb/IIIa on platelets a three-antibody mixture was separately
added to each sample of whole blood: mouse anti-human PAC-
1:FITC (1:100, to detect the activated GPIIb/IIIa receptor, Becton
Dickinson, San Jose, CA), mouse anti-human CD42b:RPE-Cy5
andmouseanti-humanCD38:RPE(1:60,BDBiosciences)ormouse
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related antigen CD11b on leukocytes was detected by incubation
with a mixture of mouse anti-human CD11b:FITC (1:10, Dako),
mouse anti-human CD42b:RPE-Cy5 and mouse anti-human
CD38:RPE or mouse anti-human CD66:RPE. Mouse IgG1:FITC
(1:10, Dako) and mouse IgM:FITC (1:100, Becton Dickinson) were
used as control antibodies for CD11b and PAC-1, respectively.
Tissue factor expression
A three antibody mixture was added to whole blood containing
mouse anti-human CD142:RPE (1:30, BD Biosciences) to detect
tissue factor, mouse anti-human CD42b:RPE-Cy5 and mouse
anti-human CD38:FITC or mouse anti-human CD66:FITC or
their respective control antibodies. Mouse IgG1:RPE (1:30, BD
Biosciences) was the control for the anti-CD142:RPE antibody.
Microparticle isolation
Whole blood was stimulated with agonists as described above
and centrifuged to platelet-poor-plasma. Microparticles were
isolated as previously described [18] and incubated with Annexin
V-Cy5 (1:100, BD Biosciences) [18], mouse anti-human tissue
factor CD142:RPE and mouse anti-human CD42b:FITC or
mouse anti-human CD38:FITC, alternatively mouse anti-human
CD66:FITC, simultaneously or isotype controls IgG1:FITC and
IgG1:PE (all from BD Biosciences).
Isolation of platelets, neutrophils, and monocytes
Platelets were purified from platelet-rich-plasma as previously
described [21]. Neutrophils and monocytes were isolated from
heparinized peripheral blood collected from healthy donors using
a one-step density gradient centrifugation with PolymorphprepH
(Nycomed, Oslo, Norway). Leukocytes were resuspended in
RPMI-1640 at a concentration of 1610
6/mL.
Binding of Stx2 and O157LPS to platelets and leukocytes
Binding of Stx2 to platelet-leukocyte aggregates or to free
(unbound) platelets, monocytes or neutrophils was assayed in
whole blood, incubated with Stx2 (200 pg/mL) for 30 min at
37uC and the antibody combinations described above. Erythro-
cytes were lysed with FACSLyse and cells were washed twice with
PBS and incubated with a mouse monoclonal anti-Stx2 IgG1
antibody (11E10, 200 ng/mL, a gift from T.G. Obrig) or mouse
IgG1 (Dako) diluted in 0.1% Saponin (Sigma-Aldrich)/PBS for
30 min at room temperature. After washing, the blood cells were
incubated with rabbit anti-mouse:RPE F(ab9)2 (1:1000, Dako,
diluted in 0,1% Saponin/PBS), as the secondary antibody for
30 min at room temperature. Specificity of the secondary antibody
was tested by omitting the primary antibody. Stx2 binding was
also examined on purified platelets, monocytes and neutrophils
and binding was detected in a similar manner. O157LPS binding
was detected as previously described [21].
Flow cytometry acquisition and interpretation of data
Flow cytometry was performed using a FACSCalibur instrument
with CELLQuest software (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Forward and side scatter measurements
were made with gain settings in linear mode for the analysis of
platelet-monocyte or platelet-neutrophil interactions. The mono-
cyte and the neutrophil populations were thus easily distinguished
(Figure 1A). A minimum of 2000 monocytes and 5000 neutrophils
were acquired for each determination. A three-color analysis was
used for simultaneous detection of platelet-leukocyte aggregates and
platelet-leukocyte activation. Monocytes and neutrophils were
further gated into a CD42b-positive platelet-bound population,
gate two, and a CD42b-negative platelet-free population, gate three
(FL1 versus FL3, Figure 1B).
Determination of surface-bound TF or Stx on platelet-leukocyte
aggregates was performed using a three-color analysis procedure
for simultaneous detection of platelet-leukocyte aggregates and TF
or Stx2 presence on blood cell aggregates. In the platelet-bound
leukocyte population (gate two) the FL1 versus FL2 cytograms
were used to estimate the percentage of platelet-leukocyte
aggregates with bound TF or Stx2 (Figure 1C). Similarly, the
FL1 versus FL2 cytograms were used to estimate the percentage of
TF or Stx2 in the platelet-free leukocyte population. Unbound
platelets were measured with forward and side scatter signals in
logarithmic mode. 10 000 events were acquired with a live gate on
FSC versus SSC. Results were compared to antibody-matched
controls (Figure 1D) and expressed as percentage positive cells or
as mean fluorescence intensity (MFI) after subtraction of the
control antibodies. Microparticles were defined and detected as
previously described [18].
Flow chamber perfusion studies
Wholeblood was perfused through a modification of a parallel flow
chamber [30] surrounded by an incubation hood, adjusting the
temperature to 37uC. Defined shear rates between 100–340 s
21 and
1000–2000 s
-1 were generated with a syringe pump in withdrawal
mode (Harvard Apparatus Inc, Holliston, MA). Immediately before
perfusion PBS (1:500, PBS:blood), Stx2, O157:H7LPS, O111:B4LPS
or a combination of Stx2/O157:H7LPS or Stx2/O111:B4LPS were
added to the blood. After 15 minutes perfusion the blood was
collected and kept on ice for flow cytometry experiments as described
above or centrifuged to platelet-poor-plasma for measurement of TF
procoagulant activity.
Tissue factor procoagulant activity assay
Tissue factor procoagulant activity (TF) in plasma was measured
with ActichromeH TF (product nr 846, American Diagnostica Inc,
Stamford, CT). Whole blood was incubated with Stx2 (200 pg/
mL) and/or O157:H7LPS (1 mg/mL) or O111:B4LPS (1 mg/mL)
for 4 h before centrifugation to obtain platelet-poor-plasma.
Plasma samples (from flow chamber experiments or after 4 h
incubation with the agonists) were used. Samples were stored at
280uC until assayed.
Statistical analysis
Differences between whole blood and isolated blood cells,
incubated with the various stimulants or left unstimulated, were
assessed by the Mann-Whitney U-test. A P-value of 0.05 or lower
was considered significant. Statistical analyses were performed
using SPSS version 11 (SPSS, Chicago, IL).
Results
Stx2 and EHEC-LPS induce platelet-leukocyte aggregate
formation
Incubation of whole blood with Stx2 for 4 h induced a
significant increase in platelet-monocyte but not platelet-neutro-
phil aggregate formation (Figure 2A and 2B) while LPS induced
both platelet-monocyte and platelet-neutrophil aggregate forma-
tion (Figure 2A and 2B). All LPS serotypes tested (O157:H7,
O103:H2, O111:HN, O121:H19 or O111:B4) induced increased
aggregate formation, although O157:H7LPS was more potent
compared to the other serotypes (Figure 2C and 2D). For both
stimulants more aggregates were observed between platelets and
monocytes than between platelets and neutrophils.
Blood Cell Complexes/TF in HUS
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neutrophil aggregate formation was noted when blood cells were
co-stimulated with Stx2 and LPS simultaneously, in comparison to
Stx2 or LPS alone (Figure 2A and 2B). The results show that both
Stx2 and O157LPS induce platelet-monocyte aggregate forma-
tion, that co-stimulation with Stx2 and LPS had an additive effect
and that O157LPS was a more potent trigger of platelet-leukocyte
aggregate formation than other LPS serotypes.
PAC-1 binding to leukocyte-bound and -free platelets as
a marker for platelet activation
Platelet activation was detected in whole blood after incubation
with Stx2, O157LPS or O111:B4LPS by binding of the PAC-1
antibody to platelets in complex with monocytes or with
neutrophils (Figure 3A) as well as to unbound platelets stimulated
with LPS. An increase in binding of the PAC-1 antibody was
detected on leukocyte-bound platelets in whole blood stimulated
with Stx2 although no effect was noted on unbound platelets.
Whole blood stimulated with LPS exhibited even more platelet
activation in comparison to whole blood incubated with Stx2 and
the PBS-control.
Surface expression of CD11b on platelet-bound and
platelet-free monocytes and neutrophils as a marker of
leukocyte activation
Whole blood incubated with Stx2 exhibited increased monocyte
and neutrophil surface expression of CD11b (Figure 3B and 3C),
albeit to a lesser extent compared to LPS (O157:H7 or O111:B4).
Stx2 stimulation increased CD11b expression in platelet-bound as
well as in platelet-free monocytes whereas only a weak increase
was detected in neutrophils in complex with platelets and no
increase was seen in platelet-free neutrophils (Figure 3C). LPS
stimulation increased the intensity of CD11b staining on
monocytes and neutrophils in complex with platelets more than
visualized on unbound monocytes/neutrophils. Incubation with
PBS did not induce increased CD11b surface expression. Thus
both Stx2 and O157LPS induced platelet and leukocyte activation
which was more notable when cells were in complex.
Stx2 and EHEC-LPS induce tissue factor expression on
platelet-leukocyte aggregates
Directly after blood sampling unstimulated cells in whole blood
showed low baseline levels of TF. TF expression was detected on
8% of platelet-monocyte aggregates (range 4–12%, 7 experiments)
but not on platelet-neutrophil aggregates or unbound cells (data
not shown). Incubation of PBS-treated whole blood at 37uC for
4 h increased the population of platelet-monocyte and platelet-
neutrophil aggregates with surface-bound TF minimally
(Figure 4A). Incubation of whole blood with Stx2 and/or LPS
for 4 h induced a significant increase of platelet-monocyte
aggregates expressing TF (Figure 4A) compared to PBS-treated
samples. LPS induced increased platelet-neutrophil aggregates
with surface-bound TF, whereas Stx only had a negligible effect
(Figure 4B). TF bound to monocytes and neutrophils in complex
Figure 1. Detection of platelet-monocyte or platelet-neutrophil aggregates and tissue factor expression by flow cytometry. (A) The
neutrophil and monocyte population were identified in whole blood by their characteristic size and granularity. In the monocyte gate 98% of the cells
were positive for the monocyte marker CD38:FITC and 99% of the cells in the neutrophil gate were CD66:FITC positive showing the accuracy of the
identification of cells by forward and side scatter. (B) Monocytes or neutrophils in complex with platelets (gate 2), were identified by binding of
CD38:FITC or CD66:FITC (FL1) and the platelet specific antibody CD42b:RPE-Cy5 (FL3). Cells in gate 3 represent platelet-free monocytes or neutrophils.
(C) Surface bound tissue factor was identified by binding of CD142:RPE and CD38:FITC or CD66:FITC (FL2 vs. FL1). (D) Percentage of positive cells was
calculated by subtraction of the negative control antibody.
doi:10.1371/journal.pone.0006990.g001
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Incubation of whole blood with a combination of Stx2 and LPS
(O157:H7LPS or O111:B4LPS) induced a significant increase in
platelet-monocyte aggregates as well as platelet-free monocytes
expressing TF compared to Stx2 or LPS alone. A similar, albeit
weaker, effect was noted on platelet-bound or platelet-free
neutrophils. All LPS serotypes tested showed similar results
although O157:H7LPS was slightly more potent (Figure 5A
and 5B).
Taken together these results show that Stx2, O157LPS and
Stx2/LPS induce a significant increase in TF expression,
predominantly on platelet-monocyte aggregates, that the combi-
nation of Stx2 and LPS had an additive effect on TF-expression on
platelet-monocyte aggregates, and that O157LPS was slightly
more potent than the other LPS serotypes.
Stx2 and EHEC-LPS induce tissue factor–positive
microparticles
Levels of microparticles generated by incubation of whole blood
with Stx2 or LPS were significantly higher compared to PBS-
treated blood (Table 1). The highest numbers of microparticles
were generated by incubation with LPS. O157:H7LPS generated
more microparticles than O111:B4LPS. A significant increase in
platelet microparticle generation and numbers of microparticles
expressing TF was noted in whole blood co-stimulated with Stx2/
LPS compared to each agonist alone (P,0.05). For all agonists
tested platelet microparticles constituted the largest proportion of
total microparticles followed by microparticles of monocyte origin.
Similarly, TF-positive microparticles were considerably more
elevated in whole blood incubated with an agonist than in PBS-
treated blood.
Stx2 binds to monocytes and to activated platelets
Results shown above indicated that Stx2 alone did not have as
profound effect on platelet-leukocyte aggregate formation, platelet
or leukocyte activation and TF-positive microparticle generation
as LPS, and since this response was mostly demonstrated in
monocytes, we examined the ability of Stx2 to bind to platelets,
monocytes and neutrophils. Stx2 was added to whole blood or to
isolated platelets, monocytes or neutrophils. The results are
summarized in Table 2 and showed that Stx bound mostly to
monocytes and platelets, particularly after activation, and that
minimal binding to platelet-free neutrophils was detected. There
was no binding of Stx2 to platelet-bound neutrophils and no
binding was detected when the primary anti-Stx2 antibody was
omitted.
Figure 2. Platelet-monocyte and platelet-neutrophil aggregates induced by incubation with Stx2 and/or LPS determined by flow
cytometry. (A) Incubation of PBS-treated whole blood at 37uC for 4 h induced a slight increase in platelet-monocyte (A) and platelet-neutrophil (B)
aggregate formation compared to baseline levels. Baseline levels of platelet-monocyte aggregates were 10% (range 5–17%, 7 experiments) and
platelet-neutrophil aggregates 6% (range 2–13%, 7 experiments). Incubation of whole blood with Stx2 and/or O157LPS (0.5 mg/mL) induced
predominantly the formation of platelet-monocyte aggregates. (C) Incubation of whole blood with O157LPS (1 mg/mL) at 37uC for 4 h induced
significantly more aggregate formation between platelets and monocytes in comparison to the other LPS serotypes tested while no significant
differences, between LPS serotypes, were observed in platelet-neutrophil (D) aggregate formation. Results are expressed as the percentage of the
monocyte or neutrophil population that was positive for CD38:FITC or CD66:FITC as well as the platelet specific marker CD42b:RPE-Cy5. Data are
expressed as mean6standard deviation (n=10 experiments), ** denotes P,0.01 when comparing aggregate formation in whole blood incubated
with a stimulant and PBS-treated whole blood and * denotes P,0.05, comparing aggregate formation in whole blood incubated with O157LPS with
those incubated with O103, O111, O121, or O111:B4LPS. NS; indicates not significant.
doi:10.1371/journal.pone.0006990.g002
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formation and tissue factor expression under shear stress
Perfusion of whole blood at shear rates between 100–340 s
21 or
1000–2000 s
21 with Stx2, O157LPS (1 mg/mL) or O157LPS/
Stx2 through a parallel plate flow chamber increased platelet-
monocyte aggregates considerably (Figure 6A) compared to PBS-
stimulated whole blood. Similarly, O111:B4LPS alone or in
combination with Stx2 increased platelet-monocyte aggregates.
Higher shear rates (1000–2000 s
21) induced more platelet-
monocyte aggregate formation in the presence of Stx2 or
O157LPS than lower shear rates (Figure 6A). Notably, the
combination of Stx2/O157LPS at the lower shear rate increased
platelet-monocyte aggregates two-fold in comparison to each
agonist alone. Combination of low or high shear and Stx2,
O157LPS or both simultaneously induced only a slight increase in
platelet-neutrophil aggregates (Figure 6B).
Stx2, O157LPS or O111:B4LPS or Stx2/LPS increased the
number of platelet-monocyte aggregates with surface-bound TF at
both low and high shear rates (Figure 6C). A marked increase in
platelet-monocyte aggregates with surface-bound TF was noted in
whole blood co-stimulated with Stx2/LPS at higher shear rates.
The effect of shear-stress on platelet-neutrophil aggregates
expressing TF was minimal (Figure 6D). Thus a most potent
additive effect regarding TF-expression was noted on platelet-
monocyte aggregates exposed to Stx2/LPS at high shear rates.
Stx 2 and EHEC-LPS induce release of functional tissue
factor into plasma under shear stress
To examine the levels of functional TF in plasma the
procoagulant activity of TF was measured. Plasma levels of
functional TF were examined after incubation of whole blood with
Stx2, O157:H7LPS or O111:B4LPS or LPS/Stx2 for 4 h. All
agonists tested, alone or in combination, induced increased plasma
levels of functional TF, with a minimal additive effect when
agonists were combined (Table 3).
Stx2, LPS (O157:H7 or O111:B4) or Stx2/LPS were added to
whole blood immediately before perfusion through a parallel plate
flow chamber. At low shear rates (100–340 s
21) Stx2, both LPS
serotypes tested and Stx2/LPS induced increased release of
functional TF into plasma in comparison to unstimulated-
(Table 3) or PBS- treated whole blood (data not shown). The
highest amount of functional TF in plasma was noted at shear
rates between 1000–2000 s
21 but no additive effect was
demonstrated when agonists were combined. Thus both Stx2
and O157LPS induced a marked release of functional TF into
plasma, especially when shear forces were added.
HUS patients have TF–positive circulating platelet-
monocyte and platelet-neutrophil aggregates
Platelet-monocyte and platelet-neutrophil aggregates were
examined in whole blood from four children with HUS during
the acute phase of disease and after recovery. Significantly higher
levels of platelet-monocyte as well as platelet-neutrophil aggregates
(Figure 7A and 7B) were observed in the patients during the acute
phase but not after recovery. Levels at recovery were slightly
higher compared to those found in normal adults as shown in
Figure 1 (n=10).
Expression of surface-bound TF was examined during the acute
phase of HUSand afterrecovery.In the acute phase all patients had
significantly elevated levels of platelet-monocyte as well as platelet-
neutrophil aggregates expressing surface-bound TF as compared to
afterrecovery(Figure7Cand7D).Levelsatrecoverywere similarto
those found in normal adults as shown in Figure 2 (n=10).
Plasma from HUS patients has increased levels of TF and
TF–expressing microparticles
Plasma levels of functional TF were studied during the acute
phase and compared to pediatric controls (n=4). Plasma TF levels
in HUS patients (median 362, range 270–420 pg/mL) were
considerably higher than those in pediatric controls (median 102,
Figure 3. Activation status of platelets, monocytes, and
neutrophils stimulated with Stx2, and LPS. (A) Incubation of
whole blood with Stx2, O157:H7LPS (1 mg/mL) or O111:B4LPS (1 mg/mL)
induced PAC-1 binding to platelets in complex with monocytes or
neutrophils as determined by flow cytometry. LPS also induced PAC-1
binding to unbound platelets. (B) Stx2, O157:H7LPS or O111:B4LPS
stimulation induced CD11b expression on monocytes and (C) on
neutrophils in complex with platelets although the effect of Stx2 on
neutrophils was minimal. For all markers O157LPS was more potent
than all other LPS serotypes tested. Results are expressed as a mean of
mean fluorescence intensity (MFI)6standard deviation (six experi-
ments), *** denotes P,0.001, ** P,0.01 and * P,0.05 when comparing
PAC-1 or CD11b expression in whole blood incubated with stimulant
with PBS-treated whole blood.
doi:10.1371/journal.pone.0006990.g003
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phase of disease showed considerably higher levels of micropar-
ticles compared to after recovery (Table 4), most of the
microparticles were of platelet origin. TF-expressing microparti-
cles were elevated during the acute phase of disease.
Stx2 is present on platelet-monocyte and platelet-
neutrophil aggregates from patients with HUS
Stx2 was detected on circulating platelet-monocyte (median
39%, range 22–49%) and platelet-neutrophil aggregates (median
24%, range 9–43%) from all patients with HUS during the acute
phase of disease. In addition, all patients had Stx2 bound to their
platelet-free monocytes (median 37%, range 30–41%), platelet-
free neutrophils (median 22, range 17–32%) as well as to their
unbound-platelets (median 55%, range 39–82%). After recovery
no binding of the antibodies was detected. As a control, no binding
of the anti-stx2 antibody was detected on blood cells from the
three patients with acute renal failure indicating that antibody
binding was not due to cell changes related to acute renal failure.
O157:H7LPS is present on platelets, monocytes, and
neutrophils from patients with HUS
O157:H7LPS was detected on platelets (median 51%, range
35–56%), monocytes (median 55%, range 51–90%) and neutro-
phils (median 61%, range 49–72%) from three of the HUS
patients. Binding of the anti-O157 antibody was not detected on
blood cells from the patient from whom the fecal E. coli O98:H21
serotype was isolated. Binding of O157:H7LPS to platelet-
Figure 4. TF expression on blood cells in complex and free cells induced by incubation with Stx2 and/or LPS. (A) Incubation of whole
blood with Stx2 or O157:H7LPS (0.5 mg/mL) induced TF expression mostly on platelet-monocyte aggregates and to a lesser degree on unbound
monocytes as determined by flow cytometry. (B) Likewise, in the neutrophil population TF expression was mostly seen on neutrophils in complex
with platelets. Data are expressed as percentage of the platelet-monocyte or platelet-neutrophil population or percentage of unbound monocytes or
neutrophils that were positive for the TF antibody6standard deviation (n=10). ** denotes P,0.01 and * P,0.05, when comparing TF expression on
aggregates in whole blood incubated with Stx2, LPS or the Stx2/O157LPS combination with unstimulated PBS-treated whole blood (except when
comparisons are delineated). NS; indicates not significant.
doi:10.1371/journal.pone.0006990.g004
Figure 5. LPS–induction of TF expression on platelet-leukocyte aggregates. Incubation of whole blood with O157LPS (1 mg/mL) induced
slightly more TF expression compared to other LPS serotypes tested. Data are expressed as percentage of the platelet-monocyte (A) or platelet-
neutrophil population (B) that were positive for the TF antibody6standard deviation (n=10). * denotes P,0.05, comparing TF expression on blood
cell aggregates incubated with O157LPS with those incubated with O103, O111, O121, or O111:B4LPS.
doi:10.1371/journal.pone.0006990.g005
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After recovery no binding of the antibody was detected.
Discussion
Tissue factor expressing microparticles are procoagulant [31].
In this study we demonstrate circulating TF-expressing platelet-
leukocyte aggregates and microparticles in blood samples from
HUS patients. Platelet-leukocyte aggregate formation was gener-
ated in vitro in normal whole blood stimulated with Stx2 and/or
O157LPS under shear flow, microparticles were released and TF
was demonstrated on platelet or monocyte-derived microparticles
after stimulation. EHEC-associated HUS is known to be a
prothrombotic condition [32]. This activity is related to Stx and
LPS-induced endothelial cell injury [24] as well as a direct
interaction between EHEC virulence factors, Stx and LPS, and
platelets, leading to platelet activation [21,27]. Direct contact
between EHEC virulence factors and blood cells, as shown here,
leads to TF expression, which would thus trigger thrombosis.
Increased levels of circulating platelet-leukocyte aggregates
expressing TF have been found in patients with acute coronary
syndrome [33] and in an in vivo model of experimental
endotoxemia [34]. TF has been found to play a key role in sepsis
[13] and infectious endocarditis [35] and procoagulant micropar-
ticles expressing TF have been demonstrated in meningococcal
sepsis [36] and in thrombotic microangiopathies [18,37]. This pro-
thrombotic pathway, ultimately generating thrombin, is opera-
tional during HUS as it has been shown that TF is elevated during
HUS [17]. In vitro studies have shown that TF expression is
increased in human glomerular endothelial cells stimulated with
Stx1 and TNF-a and further enhanced by exogenous angiotensin
II [38]. Similarly, stimulation of macrophage-like THP-1 cells with
Stx1 induces expression of TF [39]. Intravenous injection of
C57BL/6 mice with Stx2 and/or LPS has been shown to induce
TF expression in the kidneys and increase thrombin generation
(detected by levels of thrombin-antithrombin III complex)
indicating increased coagulability [40]. The mechanism by which
TF elevation in the circulation occurs in HUS has not been
previously studied. We therefore added EHEC virulence factors to
normal whole blood with and without application of shear stress
under flow, in order to study their effect on microparticle
generation and TF expression. Both Stx2 and LPS induced
platelet-leukocyte aggregate formation, TF expression and micro-
particle generation. Co-stimulation with Stx2 and LPS resulted in
an additive effect with regard to platelet-monocyte aggregate
formation and TF expression on these aggregates, particularly
when high shear forces were applied. The additive effect of both
Stx2 and LPS was also demonstrated regarding microparticle
generation, especially platelet-derived microparticles. The physi-
ological relevance of these in vitro findings was confirmed in
patient samples in which platelet-leukocyte aggregates and TF-
bearing microparticles were demonstrated.
Table 1. Numbers and cellular origin of microparticles released from blood cells as determined by flow cytometry.
Annexin V positive
microparticles (x10
3/mL)
CD42b positive micro-
particles (x10
3/mL)
CD38 positive micro-
particles (x10
3/mL)
CD66 positive micro-
particles (x10
3/mL)
TF positive micro-
particles (x10
3/mL)
Agonist
Unstimulated 280 (249–304) 202 (174–234) 39 (37–62) 0.5 (0.2–0.7) 67 (34–88)
Stx2 1958 (1871–2039)* 1088 (821–1298)* 26 (15–34)* 0.4 (0.1–0.6) * 670 (463–847)*
O157:H7LPS 3095 (2678–3484)* 2200 (1514–2590)* 189 (132–291)* 2.0 (1.3–2.6) * 1791 (1207–2257)*
O111:B4LPS 2314 (2002–2861)* 1564 (1073–1991)* 112 (71–150)* 2.1 (1.5–2.6) * 1195 (813–1385)*
Stx2/O157:H7LPS 3484 (2739–3587)* 2901 (2364–3112)* 197 (121–207)* 2.7 (1.7–3.9) * 2816 (2241–3283)*
Stx2/O111:B4LPS 2977 (1895–4059)* 2674 (1341–3533)* 188 (58–303)* 2.4 (1.9–3.7) * 1953 (1679–2968)*
Data are expressed as median and range of microparticles positive for each surface marker/mL of plasma from four different experiments. *; denotes P value ,0.05
comparing microparticle generation in whole blood stimulated with Stx2, O157:H7LPS (1 mg/mL), O111:B4LPS or Stx2/LPS with unstimulated whole blood. The number
of microparticles per mL plasma was calculated as previously described [18].
doi:10.1371/journal.pone.0006990.t001
Table 2. Binding of Stx2 to blood cells in whole blood and to isolated blood cells.
Whole blood Isolated blood cells
Isolated blood cells
fMLP stimulation
Isolated blood cells
ADP stimulation
Unstimulated ,0.4 ,0.4 ,0.4 ,0.4
Monocytes Platelet-bound 27% (10–55%)**
Platelet-free 41% (24–56%)**
40% (30–51%)** 65% (58–88%)** NA
Neutrophils Platelet-bound ,0.4
Platelet-free 4% (0.75–7%)**
,0.4 ,0.4 NA
Platelets 8% (5–9%)** ,0.4 NA 49% (36–69%)**
Data are expressed as (%) of cells positive for Stx2 and shown as median and range from five different experiments. NA; not analyzed. **; denotes P value ,0.01 when
comparing Stx2 binding to monocytes, neutrophils or platelets to unstimulated whole blood or to isolated unstimulated cells.
doi:10.1371/journal.pone.0006990.t002
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bound to platelets [21] and neutrophils [41,42] although the
binding of Stx on neutrophils has been questioned [43]. We show
that Stx did not bind to resting platelets in vitro (Table 2) but
bound to activated platelets. This result confirms previous findings
[27,44]. Stx could also bind to monocytes [45] (resting or
activated) but did not bind to neutrophils (resting or activated).
Interestingly, experiments using whole blood from HUS patients
showed that Stx was bound to leukocyte-platelet aggregates
composed either of neutrophils or of monocytes but was also
present on neutrophils and monocytes that were not in complex
with platelets. The discrepancy between our in vitro results and the
results from patient blood samples may be explained by other
activation factors present in HUS plasma not accounted for in the
Figure 6. Platelet-monocyte and platelet-neutrophil aggregate formation and TF expression induced by shear and Stx2 and/or LPS.
Stx2, O157:H7LPS, O111:B4LPS (both LPS serogroups at 1 mg/mL) or a combination of Stx2 and LPS were added to whole blood immediately before
perfusion of whole blood through a flow chamber system and aggregate formation and tissue factor expression determined by flow cytometry. (A)
Stx2 and/or LPS induced platelet-monocyte aggregate formation particularly at shear rates between 1000–2000 s
21 (light bars). (B) Aggregate
formation between platelets and neutrophils increased minimally by addition of Stx2 or LPS at both low (100–340 s
21) and high shear rates as
compared to PBS-treated samples. (C) Stx2 or LPS induced TF expression on platelet-monocyte aggregates at low shear rates which increased even
more at high shear rates. Expression increased markedly in Stx2/LPS stimulated samples at higher shear rates. (D) Stx2 and/or LPS induced only a
weak increase in TF expression on platelet-neutrophil aggregates. Higher shear rates did not induce more TF expression. Data are expressed as
mean6standard deviation (n=3). Statistical comparisons were not carried out as only three experiments were performed due to the large amounts
of blood required.
doi:10.1371/journal.pone.0006990.g006
Table 3. Release of functional tissue factor into plasma, as determined using ELISA.
Tissue factor in plasma (pg/mL) Tissue factor in plasma (pg/mL) Tissue factor in plasma (pg/mL)
Agonist Incubation at 37uC, 4 h Shear rate, (s
21), 37u, 100–340 Shear rate, (s
21), 37u, 1000–2000
Unstimulated 60 (52–87) 98 (70–120) 106 (90–130)
Stx2 98 (72–112) 163 (127–190) 274 (256–298)
O157:H7LPS 110 (93–127) 175 (130–230) 332 (293–377)
O111:B4LPS 112 (89–127) 151 (94–176) 276 (241–309)
Stx2/O157:H7LPS 125 (97–145) 196 (158–207) 341 (326–367)
Stx2/O111:B4LPS 119 (93–135) 181 (148–200) 321 (294–344)
Data are expressed as pg of active tissue factor/mL of plasma and shown as median and range from three different experiments. Whole blood was incubated with
agonists for 4 h or exposed to a flow system under controlled shear rates.
doi:10.1371/journal.pone.0006990.t003
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phase of HUS appear to be able to bind Stx and our results
indicate that Stx circulates bound to leukocytes, platelets and
blood cell aggregates.
High peripheral blood neutrophil counts at presentation of
HUS were previously associated with poor outcome [46].
Neutrophil influx into the renal cortex during HUS has been
related to severe prognosis and death [47]. Upon activation,
neutrophils may express TF [10], tether to and roll on altered
endothelium. Higher neutrophil counts may form more aggregates
with platelets leading to more TF release, which may, in part,
explain why neutrophilia is associated with a worse prognosis.
O157LPS was a more potent inducer of leukocyte-platelet
aggregate formation and TF expression than other LPS serotypes.
Previous in vitro studies have shown that LPS can induce
leukocyte-platelet aggregate formation and TF expression on
leukocytes [48,49] as well as endothelial cells [50]. Furthermore,
TF is elevated during systemic endotoxemia [51]. HUS differs
from systemic endotoxemia in that there is no consumption of
plasma coagulation factors. O157LPS injected intraperitoneally
into mice leads to TLR4-mediated thrombocytopenia [21]. The
LPS found in the circulation in EHEC-associated HUS is,
however, not free in the circulation [52] but bound to patient
platelets [21] as well as neutrophils and monocytes, as shown here.
The process by which LPS activates platelets and leukocytes,
leading to shedding of TF-bearing microparticles, is enhanced in
the presence of high shear, which mimics the high shear forces
found in vivo in the glomerular capillaries of the renal cortex. This
could explain the formation of microthrombi in this location,
where the typical lesions is seen in HUS [19].
LPS binds to platelets through the TLR4/P-selectin complex
receptor [21] leading to platelet activation, demonstrated by
release of CD40 ligand and P-selectin [21]. P-selectin and CD40
ligand have been shown to be potent mediators of inflammation
[53,54]. Expression of these, and other adhesive ligands, triggers
platelet-endothelium and platelet-leukocyte interactions. Platelet
activation enables the release of chemoattractants and cytokines,
which alter the properties of vascular endothelium, promote
recruitment of monocytes and induce synthesis of TF by both
platelets and monocytes [53]. Although not addressed in this
study, endothelial cell damage will also release TF-rich micropar-
ticles [53] as could be expected during Stx-induced endothelial
Figure 7. Circulating platelet-leukocyte aggregates and TF expression in patients with HUS. (A) Patients with HUS had increased
circulating levels of platelet-monocyte and (B) platelet-neutrophil aggregates during the acute phase of disease compared to levels obtained after
recovery. TF expression on platelet-monocyte (C) and platelet-neutrophil (D) aggregates were increased during the acute phase of HUS and
decreased at recovery. Samples were available from four patients, thus precluding statistical comparisons.
doi:10.1371/journal.pone.0006990.g007
Table 4. Numbers and cellular origin of circulating microparticles and TF–expressing microparticles in plasma from HUS patients.
Annexin V positive
microparticles (x10
3/mL)
CD42b positive micro-
particles (x10
3/mL)
CD38 positive micro-
particles (x10
3/mL)
CD66 positive micro-
particles (x10
3/mL)
TF positive micro-
particles (x10
3/mL)
HUS acute phase 1568 (1327–2001) 1277 (978–1615) 102 (88–123) 1.9 (1.4–2.3) 782 (593–1216)
Recovery 512 (377–619) 407 (335–459) 51 (33–65) 0.6 (0.3–1.0) 163 (92–207)
Numbers and cellular origin of microparticles and microparticles with surface-bound tissue factor/mL of plasma shown as median and range values.
doi:10.1371/journal.pone.0006990.t004
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particles from their surface [18,31] and binding of P- selectin on
platelets to PSGL-1 on leukocytes will potentiate the generation
and shedding of leukocyte-derived microparticles which also bear
TF [53]. Thus multiple sources of microparticle generation and
TF expression and release may be active during HUS.
Conclusion
EHEC virulence factors Stx and LPS induce the formation of
aggregates between platelets and leukocytes. The effect was
additive when whole blood was co-stimulated with both virulence
factors and increased under conditions of high shear stress. This
process promoted the release of TF-bearing microparticles from
activated blood cells. Based on the findings presented in this work
we envisage a scenario in which EHEC virulence factors entering
the circulation activate platelets and leukocytes. The interaction
between these virulence factors and blood cells under shear flow
allows blood cell aggregate formation and decryption of TF [48],
expression of active TF on cell membranes as well as secretion of
TF-rich microparticles. This process will be enhanced by
circulating cytokines [55] and by Stx-induced vascular injury
releasing endothelial-derived microparticles. Thus microparticles
expressing TF will promote thrombogenesis during HUS.
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